1. Pink Sheet
  2. >>Archive

Pfizer Plans To Restart Tanezumab Trials In 2014

 
• By Jessica Merrill

While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.

While questions about its internal reorganization dominated Pfizer Inc.’s second-quarter earnings call on July 30, the company’s management also provided a few updates on its clinical programs. Notably, FDA’s partial clinical hold on the anti-nerve growth factor candidate tanezumab, in development for pain, has been lifted, management said. The company is planning to resume Phase III clinical testing of the product in 2014.

The resumption of the clinical program is contingent on FDA’s review of non-clinical data from tests Pfizer is currently running, Primary Care Business President John Young said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.